Skip to Main Content

Investigating novel treatments for a brighter tomorrow

See Enrolling Studies

Clinical trials are carefully designed research studies that explore if a new medication or device is safe and effective for humans. These studies may also show which medical approaches work best for certain illnesses or groups of people.

Uptown Research Institute is currently enrolling patients in clinical trials for the following:

Anxiety Outpatient

MindMed-300

This study is designed to evaluate the efficacy of a single dose of 100 µg of MM-120 (D-lysergic acid diethylamide D-tartrate), versus placebo, for the treatment of anxiety symptoms.
This study is sponsored by Mind Medicine, Inc.

Learn More
Depression Outpatient

MindMed-310

This study is designed to evaluate the efficacy of a single dose of 100 µg of MM-120 (D-lysergic acid diethylamide D-tartrate), versus placebo, for the treatment of depression symptoms.
This study is sponsored by Mind Medicine, Inc.

Learn More
Depression Outpatient

Cybin 003-002

For adults with a diagnosis of Major Depressive Disorder (MDD) currently experiencing a Major Depressive Episode (MDE).

The goal of this study is to evaluate the efficacy, safety, and tolerability of CYB003 15 mg, compared to placebo, in treating symptoms of MDD in adult participants.

This study is sponsored by Cybin.

Learn More
PTSD Outpatient

Transcend TSND201-PTSD-301

For adults living with Post Traumatic Stress Disorder (PTSD)

The purpose of this study is to assess the efficacy, safety, and tolerability of TSND-201 for the treatment of PTSD symptoms compared to placebo

This study is sponsored by Transcend Therapeutics, Inc.

Learn More
Schizophrenia Inpatient

Novartis CGXV813B12201

For adults experiencing an exacerbation of schizophrenia symptoms who require inpatient treatment

The purpose of this study is to assess the safety, tolerability, and efficacy of GXV813 on treating adults living with symptoms of schizophrenia.

This study is sponsored by Novartis.

Learn More
Schizophrenia Inpatient

Maplight-007C-MA

For adults with schizophrenia who warrant inpatient hospitalization.

The goal of this study is to assess the efficacy, safety, and tolerability of ML-007C-MA compared with placebo in reducing symptoms of schizophrenia in adults experiencing an acute exacerbation of psychosis.

This study is sponsored by Maplight Therapeutics.

Learn More
Schizophrenia Inpatient

Neurocrine-3029

For adults with schizophrenia who warrant inpatient hospitalization.

The goal of this study is to assess the efficacy, safety, and tolerability of NBI-1117568 in adults with schizophrenia.

This study is sponsored by Neurocrine Biosciences, Inc.

Learn More
Schizophrenia Inpatient

Otsuka-00035

Treatment for worsening of symptoms in patients with schizophrenia.

The primary objective of this study is to evaluate the efficacy, safety, and tolerability of SEP-363856 (75 mg to 100 mg /daily) compared to a placebo in adults experiencing an acute exacerbation of schizophrenia.

This study is sponsored by Otsuka Pharmaceutical.

Learn More
Schizophrenia Inpatient

Kynexis 5356-CL-002

For adults with schizophrenia who are clinically stable, but require treatment on their cognitive functioning.

The goal of this study is to assess the efficacy, safety, and tolerability of KYN-5356 on treating cognitive impairment in adults living with symptoms of schizophrenia.

This study is sponsored by Kynexis Therapeutics.

Learn More
Schizophrenia Outpatient

Neurocrine-3032

For adults with schizophrenia who do not warrant inpatient hospitalization.

The goal of this study is to assess the efficacy, safety, and tolerability of NBI-1117568 in adults with schizophrenia.

This study is sponsored by Neurocrine Biosciences, Inc.

Learn More
Schizophrenia Outpatient

Bristol Myers Squibb CN012-0068

The purpose of this study is to assess the efficacy, safety, and tolerability of KarXT on voiding dynamics and urological safety in adults living with symptoms of schizophrenia.

Participants will be asked to pass urine into a funnel or special commode connected to a Flowstar Compact Digital Uroflowmeter. This device automatically measures urine flow and volume and provides a standard printout in real time. The device is FDA 510(k) cleared.  Post-void Residual Volume Measurement (PVR) test measures the amount of urine left in the bladder after urination. Participants will lie in a supine position, a gel will be applied to the lower abdomen, and PVR will be measured using a portable bladder scanner.


This study is sponsored by Bristol Myers Squibb.

Learn More

Uptown Research Institute offers an array of clinical trials across a variety of psychiatric and medical conditions.

Clinical researchers

We follow ethical and legal guidelines to meet FDA requirements, protect patient volunteers, preserve the integrity of the study, and ensure privacy.

In order to participate in a clinical trial, patients must sign an Informed Consent Form. This document describes the rights and responsibilities for participants, including the voluntary nature of participation.

Criteria For Enrollment

Not every person can participate in a clinical trial. All clinical trials have guidelines regarding who can participate, such as:

Checkmark

Inclusion Criteria, or factors that allow someone to participate in a clinical research trial

Exclusion

Exclusion Criteria, or factors that exclude someone from participation in a clinical research trial

Inclusion and exclusion criteria may include factors like:

Age

Age

Type and stage of disease

Type and stage of disease

Previous treatment history

Previous treatment history

Other medical conditions

Other medical conditions